- Home
- KIDS vs INBX Comparison
KIDS vs INBX Comparison
Compare KIDS & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KIDS | INBX |
|---|---|---|
| Founded | 2007 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 524.3M | 430.2M |
| IPO Year | 2017 | 2020 |
Fundamental Metrics
Financial Performance| Metric | KIDS | INBX |
|---|---|---|
| Price | $18.53 | $84.15 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 2 |
| Target Price | ★ $24.75 | N/A |
| AVG Volume (30 Days) | 210.9K | ★ 246.8K |
| Earning Date | 10-28-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $227,410,000.00 | $1,400,000.00 |
| Revenue This Year | $16.58 | $563.00 |
| Revenue Next Year | $12.46 | $230.77 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 19.90 | N/A |
| 52 Week Low | $15.28 | $10.81 |
| 52 Week High | $27.60 | $94.47 |
Technical Indicators
Market Signals| Indicator | KIDS | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 58.15 | 56.66 |
| Support Level | $17.78 | $79.00 |
| Resistance Level | $19.53 | $94.47 |
| Average True Range (ATR) | 0.75 | 6.13 |
| MACD | 0.09 | -1.09 |
| Stochastic Oscillator | 62.57 | 34.79 |
Price Performance
Historical ComparisonAbout KIDS OrthoPediatrics Corp.
OrthoPediatrics Corp is a medical device company. The company is engaged in providing products to the pediatric orthopedic market. The firm designs develop and commercialize implants and instruments to meet the needs of surgeons and patients. Its products, include PediLoc, PediPlates, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc Tibia and ACL Reconstruction System among others.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.